Cutting the Brakes on Ras—Cytoplasmic GAPs as Targets of Inactivation in Cancer
Open Access
- 20 October 2020
- Vol. 12 (10), 3066
- https://doi.org/10.3390/cancers12103066
Abstract
The Ras pathway is frequently deregulated in cancer, actively contributing to tumor development and progression. Oncogenic activation of the Ras pathway is commonly due to point mutation of one of the three Ras genes, which occurs in almost one third of human cancers. In the absence of Ras mutation, the pathway is frequently activated by alternative means, including the loss of function of Ras inhibitors. Among Ras inhibitors, the GTPase-Activating Proteins (RasGAPs) are major players, given their ability to modulate multiple cancer-related pathways. In fact, most RasGAPs also have a multi-domain structure that allows them to act as scaffold or adaptor proteins, affecting additional oncogenic cascades. In cancer cells, various mechanisms can cause the loss of function of Ras inhibitors; here, we review the available evidence of RasGAP inactivation in cancer, with a specific focus on the mechanisms. We also consider extracellular inputs that can affect RasGAP levels and functions, implicating that specific conditions in the tumor microenvironment can foster or counteract Ras signaling through negative or positive modulation of RasGAPs. A better understanding of these conditions might have relevant clinical repercussions, since treatments to restore or enhance the function of RasGAPs in cancer would help circumvent the intrinsic difficulty of directly targeting the Ras protein.This publication has 150 references indexed in Scilit:
- A Landscape of Driver Mutations in MelanomaCell, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- A Tight Junction-Associated Merlin-Angiomotin Complex Mediates Merlin's Regulation of Mitogenic Signaling and Tumor Suppressive FunctionsCancer Cell, 2011
- Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancerJournal of Hepatology, 2011
- NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease OutcomeCell, 2010
- Methylation determines fibroblast activation and fibrogenesis in the kidneyNature Medicine, 2010
- An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κBNature Medicine, 2010
- Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in GliomagenesisCancer Cell, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Epigenetic silencing of a Ca 2+ -regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancersProceedings of the National Academy of Sciences of the United States of America, 2007